Welcome to our dedicated page for DBV Technologies news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBVT released its monthly report on voting rights and share count as of January 31, 2022. The total number of shares stood at 55,095,762, with the total gross of voting rights also at 55,095,762. The net voting rights, after accounting for shares without voting rights, totaled 54,925,155. This information ensures transparency for investors and complies with regulations set by the Autorité des Marchés Financiers.
DBV Technologies has published its Half-Year Report on the liquidity contract with ODDO BHF as of December 31, 2021.
The liquidity account contained 153,631 shares worth €175,542.33, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. In 2021's second half, 1,206 shares were purchased and 1,065 sold, totaling 455,657 shares bought for €3,256,011.54 and 379,901 sold for €2,951,075.39. DBV is advancing Viaskin™, a non-invasive immunotherapy platform targeting food allergies.
DBVT announced its monthly update on voting rights and total shares as of December 31, 2021. The total number of shares outstanding is 55,095,762, while the total gross of voting rights stands at 55,095,762. After accounting for shares without voting rights, the total net voting rights reach 54,942,131. This information complies with the regulations of the Autorité des Marchés Financiers.
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The event will be available for on-demand viewing starting January 10, 2022, at 7:00 AM ET. Investors can access the webcast on the company's website, where a replay will also be available post-event. DBV Technologies is focused on developing Viaskin™, an innovative immunotherapy platform aimed at treating food allergies, with ongoing clinical trials for Viaskin Peanut.
DBV Technologies announced plans to begin a pivotal Phase 3 study for its modified Viaskin Peanut patch aimed at children. This follows FDA feedback suggesting a sequential development approach, which DBV deemed inefficient. Instead, the company will conduct a Phase 3 placebo-controlled trial to demonstrate the patch's safety and effectiveness. In parallel, DBV has withdrawn its Marketing Authorization Application for Viaskin Peanut from the EMA due to insufficient data from a single pivotal study. The company believes that new data will better support its application for regulatory approval.
DBVT reported its monthly update on voting rights and share count as of November 30, 2021. The total number of shares stands at 55,090,362, indicating a consistent share base. The total number of voting rights is 55,090,362 gross and 54,983,362 net, after accounting for shares without voting rights. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, ensuring transparency for investors and stakeholders.
DBV Technologies, a clinical-stage biopharmaceutical company, announced participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021. CEO Daniel Tassé will engage in a fireside chat at 8am ET. A live webcast will be available on the company’s website, with a replay following the event. DBV Technologies is focused on developing Viaskin, a proprietary platform aimed at food allergy treatment through epicutaneous immunotherapy. The company's shares are traded on Euronext and Nasdaq under symbols DBV and DBVT, respectively.
DBVT has released information on the total number of voting rights and shares as of October 31, 2021. The company has a total of 55,011,687 shares, with 54,910,187 voting rights net of non-voting shares. This report complies with Article 223-16 of the General Regulations set by Autorité des Marchés Financiers. The data is crucial for shareholders and potential investors as it reflects the company's governance structure and shareholder engagement.
DBV Technologies announced it will present new long-term data from the REALISE trial at the ACAAI 2021 Annual Scientific Meeting, Nov. 4-8, 2021. The study focuses on the safety and health-related quality of life impacts of its lead product, Viaskin™ Peanut (DBV712), in children aged 4-11. An oral presentation and a poster presentation will showcase key findings from three years of data. The company aims to demonstrate the potential real-world applications of Viaskin Peanut, which targets peanut allergy treatment through a novel epicutaneous patch technology.
DBV Technologies reported its third quarter 2021 financial results on October 26, 2021, showing a net loss of $24.0 million, a decrease from $31.0 million in Q3 2020. Cash and cash equivalents fell to $98.2 million from $196.4 million at the end of 2020. Operating expenses decreased by 24% to $25.7 million, primarily due to cost containment measures and workforce reduction. Regulatory updates indicate the FDA is reviewing data before the STAMP trial can proceed, while EMA discussions are ongoing regarding Viaskin Peanut's Marketing Authorization.